-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ZIVO Bioscience (OTCMKTS:ZIVO) Stock Passes Above 50 Day Moving Average of $3.84
ZIVO Bioscience (OTCMKTS:ZIVO) Stock Passes Above 50 Day Moving Average of $3.84
Shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.84 and traded as high as $4.05. ZIVO Bioscience shares last traded at $3.75, with a volume of 15,356 shares.
ZIVO Bioscience Stock Performance
The firm has a market capitalization of $35.33 million, a price-to-earnings ratio of -3.79 and a beta of -0.04. The company has a 50-day moving average of $3.84 and a 200-day moving average of $3.59.
Get ZIVO Bioscience alerts:ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Institutional Investors Weigh In On ZIVO Bioscience
A hedge fund recently raised its stake in ZIVO Bioscience stock. Vanguard Group Inc. increased its holdings in shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 92,468 shares of the biotechnology company's stock after acquiring an additional 15,147 shares during the quarter. Vanguard Group Inc. owned approximately 0.98% of ZIVO Bioscience worth $359,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.04% of the company's stock.ZIVO Bioscience Company Profile
(Get Rating)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Read More
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.84 and traded as high as $4.05. ZIVO Bioscience shares last traded at $3.75, with a volume of 15,356 shares.
Zivo Bioscience,Inc.(场外交易市场代码:Zivo-GET评级)的股价在周五的交易中突破了50日移动均线。该股的50日移动均线为3.84美元,交易价格高达4.05美元。Zivo Bioscience的股票最新报3.75美元,成交量为15,356股。
ZIVO Bioscience Stock Performance
Zivo Bioscience股票表现
The firm has a market capitalization of $35.33 million, a price-to-earnings ratio of -3.79 and a beta of -0.04. The company has a 50-day moving average of $3.84 and a 200-day moving average of $3.59.
该公司市值为3,533万美元,市盈率为-3.79,贝塔系数为-0.04。该公司的50日移动均线切入位在3.84美元,200日移动均线切入位在3.59美元。
ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Zivo Bioscience(场外交易市场代码:Zivo-Get Rating)最近一次发布财报是在8月4日(星期四)。这家生物技术公司公布了本季度每股收益(0.22美元)。
Institutional Investors Weigh In On ZIVO Bioscience
机构投资者看好Zivo生物科学
ZIVO Bioscience Company Profile
Zivo生物科学公司简介
(Get Rating)
(获取评级)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Zivo Bioscience,Inc.是一家研发公司,致力于向动物、人类、膳食补充剂和医用食品制造商许可和销售从其专有藻类培养物中提取的天然生物活性成分。它在生物技术和农业技术部门开展业务,拥有知识产权组合,包括专有藻类和细菌菌株、生物活性分子和复合体、生产技术、栽培技术,以及应用于人类和动物健康的专利或正在申请专利的发明。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免费获取StockNews.com关于Zivo生物科学的研究报告(Zivo)
- 随着管理层重组,股市能否迅速反弹?
- MarketBeat:回顾中的一周8/29-9/2
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖,但仍被高估吗?
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得Zivo生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zivo Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧